Marktlink → Sectors → Science & Health → Healthcare

  • Updated February 27, 2026

Patent cliffs and CDMO demand reshape the landscape

Pharmaceutical M&A is driven by patent cliff urgency and manufacturing capacity scarcity. Specialty pharma companies with patented products command premium valuations. European CDMOs with GMP biologics capability are the most sought-after targets. Generics manufacturers face structural margin pressure from Asian competition and tender-based pricing.

Jeroen van den Berg

Sector Lead Science & Health • 14 years • 90+ transactions

“The pharmaceutical M&A landscape is being reshaped by two forces: patent cliffs forcing big pharma to acquire, and capacity scarcity making CDMOs the hottest targets in the sector. A European CDMO with GMP biologics capability and multi-year contracts is the single most sought-after asset type in our Science & Health portfolio right now.”

Sector at a Glance

  • Updated March 2, 2026
VALUATION RANGE

0.0x – 0.0x

↑ +0.2x vs 2024

EBITDA Multiple
Deals in 2025

0

Active Buyers

0+

Enter your figures → see your position instantly

Valuation Development

Pharma valuations peaked 2021 on COVID CDMO demand, corrected 2023, and recovered selectively with specialty and CDMO premiums.

5-Year Multiple Range

2021 PEAK

0.0x avg

COVID vaccine CDMO premium

2023 DIP

0.0x avg

Correction: funding pressure

2025 NOW

0.0x avg

Selective: specialty + CDMO premium

Subsegment Analysis

Specialty Pharma

[XX] deals in 2025

Multiple Range

0.0x – 0.0x

+0.3x
Buyer Mix
PE 25% • Strategic 65%
Key Valuation Driver
Patent-protected products, therapeutic niche, and pipeline depth
Am I in this segment? →

CDMO / CMO Services

[XX] deals in 2025

Multiple Range

0x – 0x

+0.4x
Buyer Mix
PE 40% • Strategic 45%
Key Valuation Driver
GMP capacity, biologics capability, and multi-year contract base
Am I in this segment? →

Pharma Distribution & Wholesale

[XX] deals in 2025

Multiple Range

0x – 0x

+0.1
Buyer Mix
PE 25% • Strategic 60%
Key Valuation Driver
GDP license, cold chain capability, and geographic coverage
Am I in this segment? →

Generics & OTC

[XX] deals in 2025

Multiple Range

0.0x  – 0.0x

+0.0x
Buyer Mix
PE 15% • Strategic 70%
Key Valuation Driver
Market share stability, dossier portfolio, and cost leadership
Am I in this segment? →

Buyer Landscape 2025

Overall Buyer Type Distribution

  • What drives premium valuations

Patent-protected specialty products

+0.0x to +0.0x

GMP biologics manufacturing capacity

+0.0x to +0.0x

Multi-year CDMO contracts with major pharma

+0.0x to +0.0x

European nearshoring / onshoring position

+0.0x to +0.0x

Complex formulation or delivery technology

+0.0x to +0.0x

Which of these buyers match your firm?

BuyersChecker analyzes your profile against our active buyer database.

Recent Transactions

Anonymized Marktlink cases showing the specialty and CDMO premium in pharmaceutical M&A.

Patent Premium

Specialty Pharma

Niche pharmaceutical company with 3 patented products in rare disease, strong clinical evidence base, and growing revenue across DACH and Benelux markets

REVENUE

€0.0M

EBITDA

€0.0M

MULTIPLE

0.0x

DURATION

0 months

3 patented products
Rare disease niche
85% prescription recurring

Key Insight

The 3 patented products in rare disease created a defensible niche that strategic buyers valued for portfolio expansion. The buyer was acquiring market authorization and prescriber relationships that would take 5+ years to build. Without patents, similar revenue would achieve 5-6x.

Capacity Scarcity

CDMO Services

European CDMO specializing in biologics fill-finish and aseptic manufacturing, GMP-certified with 8 major pharma clients and multi-year contracts covering 70% of capacity

REVENUE

€0.0M

EBITDA

€0.0M

MULTIPLE

0.0x

DURATION

0 months

GMP biologics certified
8 major pharma clients
70% contracted capacity

Key Insight

European biologics fill-finish capacity is the scarcest asset in pharmaceutical manufacturing. The PE buyer valued the GMP certification, 8 major pharma relationships, and 70% contracted capacity as the foundation for a pan-European CDMO platform. Capacity scarcity commanded a premium above typical manufacturing multiples.

Cold Chain Value

Distribution

GDP-licensed pharmaceutical wholesaler with temperature-controlled warehousing, serving hospitals and pharmacies across the Netherlands and Belgium

REVENUE

€0.0M

EBITDA

€0.0M

MULTIPLE

0.0x

DURATION

0 months

GDP licensed
Cold chain warehousing
60% hospital contracts

Key Insight

GMP biologics fill-finish capacity is scarce in Europe. The buyer was acquiring compliant manufacturing capacity that would take 3-5 years to build from scratch. Capacity scarcity premium was the dominant deal driver.

Margin Pressure

Generics & OTC

Manufacturer of generic solid-dose pharmaceuticals with 40+ product dossiers, aging production facility, and increasing competition from Asian manufacturers

REVENUE

€0.0M

EBITDA

€0.0M

MULTIPLE

0.0x

DURATION

0 months

40+ dossiers
Aging facility
Asian competition pressure

Key Insight

Generics manufacturing faces structural margin pressure from Asian competition and tender-based pricing. The 40+ dossier portfolio was valued, but the aging facility and low margins limited buyer interest. Generics companies investing in complex formulations or biosimilars achieve significantly higher multiples.

Recognize yourself in these cases? Compare your situation.

Market Trends 2025

Patent cliff drives strategic M&A urgency

Major patent expirations through 2030 are forcing big pharma to acquire pipelines, specialty products, and manufacturing capacity. Strategic buyers paid 20-40% higher multiples than PE on comparable assets.

Source: IQVIA Biopharma M&A 2025, FOCUS

$0B

biopharma M&A value 2024

CDMO capacity scarcity creates premiums

The European CDMO market is projected to reach $75B by 2035. Biologics manufacturing capacity is the scarcest asset, with the $16.5B Catalent-Novo deal signaling strategic importance. European CDMOs benefit from nearshoring trends.

Source: Harris Williams, Bourne Partners, DCAT

$0B

European CDMO market by 2035

European nearshoring reshapes supply chains

Europe accounts for 22.7% of global pharmaceutical sales. Onshoring and nearshoring trends, accelerated by tariff concerns and supply chain resilience mandates, are driving demand for European manufacturing capacity.

Source: Towards Healthcare, DCAT 2025

0.0%

Europe share of global pharma sales

AI accelerates drug development outsourcing

AI-driven drug discovery is accelerating pipeline development, increasing demand for CDMO services. Cell and gene therapy manufacturing grew 10% in 2024 at major CDMOs, with precision medicine requiring specialized production capacity.

Source: Bourne Partners, Lonza FY2024

0%

cell/gene therapy CDMO growth 2024

What This Means for You

Interactive tools that give you immediate insights—or full reports in your personal portal.

30 sec

Marktlink Multiple

Your estimated valuation

Direct: Indicative multiple

Portal: Detailed range + comparable deals
+ factors breakdown

Start tool

30 sec

BuyersChecker

How many buyers match you

Direct: Number of matches

Portal: Buyer profiles + alerts when
new buyers match

Start tool

30 sec

Benchmark Tool

Your performance vs sector

Direct: Position indication

Portal: Full benchmark report
+ quarterly updates

Start tool

30 sec

Buyer Appeal Scan

Which buyers want you

Direct: Top buyer type

Portal: All buyer types ranked + appeal factors
+ matching profiles

Start tool

1 min

Timing Scan

Market timing analysis

Direct: Timing score

Portal: Detailed timing report
+ market alerts

Start tool

2 min

Sale Readiness Test

How prepared are you

Direct: Readiness score

Portal: Full assessment
+ personalized action plan

Start tool

Industry Report 2025

Everything on this page, plus: 12 additional deal cases, detailed subsegment analysis, and 2026 outlook.

Follow This Sector

Receive updates when valuations change, new buyers emerge, or relevant deals close.

  • Valuation changes
  • Deal announcements
  • New buyer profiles
  • Quarterly updates